Nanyang Biologics Showcases AI Drug Discovery at COMPUTEX 2025

Nanyang Biologics (NYB) made a strong presence at COMPUTEX 2025, one of the world's premier technology exhibitions, held from May 20–23 at the Taipei Nangang Exhibition Center. The event, themed "AI Next," brought together global leaders in artificial intelligence, robotics, and next-generation technologies who are driving the future of innovation.

‍

Pioneering AI in Drug Discovery

‍

Building on our recent presence at GITEX ASIA Singapore1, NYB continues to highlight the transformative power of artificial intelligence in biotechnology. At COMPUTEX, we are showcasing our proprietary DTIGN (Drug-Target Interaction Graph Neural Network) platform, which leverages advanced machine learning to accelerate the discovery of natural compound-based therapeutics. DTIGN has demonstrated a 27% improvement in prediction accuracy over leading methods, significantly reducing early-stage drug discovery timelines and costs.

‍

Collaboration and Global Recognition

‍

Our presence at the NVIDIA Inception Startups Pavilion highlights NYB's position as a pioneer in AI-driven drug discovery. As a member of the NVIDIA Inception Program - a global accelerator supporting over 28,000 startups in AI and high-performance computing - NYB is recognized for its innovative approach and dedication to advancing precision health.

‍

‍

Recent strategic collaborations, such as our partnership with Precisya Global Inc., further strengthen our capabilities by integrating genomic big data analytics with our AI-powered compound libraries. This synergy enables us to identify and validate novel therapies for genetic diseases with unprecedented speed and precision.

‍

Commitment to Innovation

‍

‍

As highlighted at GITEX and now at COMPUTEX, NYB’s mission is to unlock nature’s therapeutic potential and deliver next-generation treatments for cancer and chronic diseases. Our ongoing partnerships with leading institutions and industry accelerators, including the NYB-NTU Joint Laboratory and Johnson & Johnson JLABS, reinforce our dedication to scientific excellence and impactful healthcare solutions.

‍